Notes
incremental cost-effectiveness ratio
Reference
Kulpeng W, et al. Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand. Clinical Therapeutics : 10 Mar 2014. Available from: URL: http://doi.org/10.1016/j.clinthera.2014.02.008
Rights and permissions
About this article
Cite this article
Dasatinib and nilotinib cost-effective options in Thailand. PharmacoEcon Outcomes News 700, 5 (2014). https://doi.org/10.1007/s40274-014-1164-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1164-9